A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment
<i>Background and Objectives:</i> This meta-analysis compared the efficacy and safety of peramivir compared to other neuraminidase inhibitors (NAIs). <i>Materials and Methods:</i> Data from PubMed, Embase, and Cochrane databases and ClinicalTrials.gov were searched until Janu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/56/2/63 |
| _version_ | 1797728065844936704 |
|---|---|
| author | Jui-Yi Chen Shih-Kai Wei Chih-Cheng Lai Teng-Song Weng Hsin-Hua Wang |
| author_facet | Jui-Yi Chen Shih-Kai Wei Chih-Cheng Lai Teng-Song Weng Hsin-Hua Wang |
| author_sort | Jui-Yi Chen |
| collection | DOAJ |
| description | <i>Background and Objectives:</i> This meta-analysis compared the efficacy and safety of peramivir compared to other neuraminidase inhibitors (NAIs). <i>Materials and Methods:</i> Data from PubMed, Embase, and Cochrane databases and ClinicalTrials.gov were searched until January 2019. Randomized controlled trials (RCTs) and observational studies (OSs) comparing peramivir with other NAIs for treating influenza were included. The Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) system was used to judge the overall certainty of evidence; the result was moderate. The primary outcome was time to alleviation of symptoms. Twelve articles involving 2681 patients were included in this meta-analysis. We used a random-effect model to pool the effect size, which is expressed as the difference in means (MD), risk ratio (RR), and 95% confidence interval (CI). <i>Results:</i> Overall, peramivir was superior to other NAIs (MD = −11.214 hours, 95% CI: −19.119 to −3.310). The incidence of adverse events (RR = 1.023, 95% CI: 0.717 to 1.460) and serious adverse events (RR = 1.068, 95% CI: 0.702 to 1.625) in the peramivir group was similar to those in the oseltamivir group. In addition, peramivir had higher efficacy than each NAI alone. <i>Conclusion:</i> In conclusion, the efficacy of peramivir might be higher than that of other NAIs, and this agent is tolerated as well as other NAIs. |
| first_indexed | 2024-03-12T11:08:30Z |
| format | Article |
| id | doaj.art-5967520594d9406c8a9ee2db52b1aa57 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T11:08:30Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-5967520594d9406c8a9ee2db52b1aa572023-09-02T03:21:37ZengMDPI AGMedicina1010-660X2020-02-015626310.3390/medicina56020063medicina56020063A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza TreatmentJui-Yi Chen0Shih-Kai Wei1Chih-Cheng Lai2Teng-Song Weng3Hsin-Hua Wang4Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan 71004, TaiwanDepartment of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 73657, TaiwanDepartment of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 71051, TaiwanDepartment of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 73657, TaiwanDepartment of Pediatrics, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan<i>Background and Objectives:</i> This meta-analysis compared the efficacy and safety of peramivir compared to other neuraminidase inhibitors (NAIs). <i>Materials and Methods:</i> Data from PubMed, Embase, and Cochrane databases and ClinicalTrials.gov were searched until January 2019. Randomized controlled trials (RCTs) and observational studies (OSs) comparing peramivir with other NAIs for treating influenza were included. The Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) system was used to judge the overall certainty of evidence; the result was moderate. The primary outcome was time to alleviation of symptoms. Twelve articles involving 2681 patients were included in this meta-analysis. We used a random-effect model to pool the effect size, which is expressed as the difference in means (MD), risk ratio (RR), and 95% confidence interval (CI). <i>Results:</i> Overall, peramivir was superior to other NAIs (MD = −11.214 hours, 95% CI: −19.119 to −3.310). The incidence of adverse events (RR = 1.023, 95% CI: 0.717 to 1.460) and serious adverse events (RR = 1.068, 95% CI: 0.702 to 1.625) in the peramivir group was similar to those in the oseltamivir group. In addition, peramivir had higher efficacy than each NAI alone. <i>Conclusion:</i> In conclusion, the efficacy of peramivir might be higher than that of other NAIs, and this agent is tolerated as well as other NAIs.https://www.mdpi.com/1010-660X/56/2/63peramivirneuraminidase inhibitorsinfluenza |
| spellingShingle | Jui-Yi Chen Shih-Kai Wei Chih-Cheng Lai Teng-Song Weng Hsin-Hua Wang A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment Medicina peramivir neuraminidase inhibitors influenza |
| title | A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment |
| title_full | A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment |
| title_fullStr | A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment |
| title_full_unstemmed | A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment |
| title_short | A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment |
| title_sort | meta analysis comparing the efficacy and safety of peramivir with other neuraminidase inhibitors for influenza treatment |
| topic | peramivir neuraminidase inhibitors influenza |
| url | https://www.mdpi.com/1010-660X/56/2/63 |
| work_keys_str_mv | AT juiyichen ametaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT shihkaiwei ametaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT chihchenglai ametaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT tengsongweng ametaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT hsinhuawang ametaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT juiyichen metaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT shihkaiwei metaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT chihchenglai metaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT tengsongweng metaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment AT hsinhuawang metaanalysiscomparingtheefficacyandsafetyofperamivirwithotherneuraminidaseinhibitorsforinfluenzatreatment |